Aratana Theraptcs Cmn (PETX) 9.13 $PETX Aratana
Post# of 273254
Posted On: 09/22/2016 9:07:49 AM
Aratana Theraptcs Cmn (PETX) 9.13 $PETX
Aratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit
PR Newswire - Wed Sep 21, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics will participate in a panel discussion at the Jefferies Animal Health Leadership Summit today in London titled "Competing with Giants: Strategies to Succeed in a Consolidated Market." The event is open to the public, but will not be webcast.
PETX: 9.13 (+0.01)
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 2.98 (+0.37), STEM: 1.36 (unch), PETX: 9.13 (+0.01), THLD: 1.22 (-0.05)
Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension)
PR Newswire - Mon Aug 15, 3:30PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016.
PETX: 9.13 (+0.01)
Aratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2%
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:45AM CDT
Aratana Therapeutics, Inc. (PETX) was a big mover last session, as the company saw its shares rise over 6% on the day.
AKAO: 4.16 (-0.05), PETX: 9.13 (+0.01)
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 11.67 (-0.33), HRTX: 19.76 (-0.10), LJPC: 26.00 (-0.27), PETX: 9.13 (+0.01)
Aratana Therapeutics Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:20PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its second quarter 2016 financial and operational results. For the quarter ended June 30, 2016, Aratana reported net income of $21.2 million or $0.61 diluted net income per share, which includes $38 million in revenue from the collaboration, license, development and commercialization agreement with Elanco Animal Health, a division of Eli Lilly and Company.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 11.67 (-0.33), JNJ: 119.18 (+0.27), HRTX: 19.76 (-0.10), GILD: 81.70 (unch), LJPC: 26.00 (-0.27), PETX: 9.13 (+0.01)
First Week of February 2017 Options Trading For Aratana Therapeutics
StockOptionsChannel.com - Tue Jun 28, 9:33AM CDT
Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration...
PETX: 9.13 (+0.01)
Aratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic
PR Newswire - Thu Jun 02, 8:23AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company received a technical section complete letter for chemistry, manufacturing and controls (CMC) for NOCITA® (bupivacaine liposome injectable suspension) from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). Nocita is being investigated as a therapeutic option to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and works as a long-acting local anesthetic designed to provide up to 72 hours of post-operative pain control.
PETX: 9.13 (+0.01)
Aratana Therapeutics to Participate at Two Upcoming Investor Conferences
PR Newswire - Mon May 23, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
PETX: 9.13 (+0.01)
Aratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution)
PR Newswire - Tue May 17, 4:46PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017.
PETX: 9.13 (+0.01)
Aratana reports 1Q loss
Automated Insights - Thu May 05, 5:38PM CDT
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $18.1 million in its first quarter.
PETX: 9.13 (+0.01)
Aratana Therapeutics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Aratana Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Mon May 02, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
PETX: 9.13 (+0.01)
Aratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health
PR Newswire - Mon Apr 25, 3:10PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals will host a conference call today, Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) that was announced this afternoon.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Aratana, Elanco Announce Global Strategic Collaboration
PR Newswire - Mon Apr 25, 3:05PM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 9.05 (+0.06), EBIO: 3.57 (+0.07), PTCT: 10.40 (-0.04), PETX: 9.13 (+0.01), ARRY: 3.59 (-0.05)
Aratana Therapeutics to Report First Quarter 2016 Financial Results
PR Newswire - Thu Apr 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
PETX: 9.13 (+0.01)
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:45AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise over 8% on the day.
CCXI: 5.16 (+0.02), PETX: 9.13 (+0.01)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 4.69 (+0.16), PETX: 9.13 (+0.01)
Aratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit
PR Newswire - Wed Sep 21, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics will participate in a panel discussion at the Jefferies Animal Health Leadership Summit today in London titled "Competing with Giants: Strategies to Succeed in a Consolidated Market." The event is open to the public, but will not be webcast.
PETX: 9.13 (+0.01)
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 2.98 (+0.37), STEM: 1.36 (unch), PETX: 9.13 (+0.01), THLD: 1.22 (-0.05)
Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension)
PR Newswire - Mon Aug 15, 3:30PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016.
PETX: 9.13 (+0.01)
Aratana Therapeutics (PETX) Worth a Look: Stock Gains 6.2%
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:45AM CDT
Aratana Therapeutics, Inc. (PETX) was a big mover last session, as the company saw its shares rise over 6% on the day.
AKAO: 4.16 (-0.05), PETX: 9.13 (+0.01)
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 11.67 (-0.33), HRTX: 19.76 (-0.10), LJPC: 26.00 (-0.27), PETX: 9.13 (+0.01)
Aratana Therapeutics Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:20PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its second quarter 2016 financial and operational results. For the quarter ended June 30, 2016, Aratana reported net income of $21.2 million or $0.61 diluted net income per share, which includes $38 million in revenue from the collaboration, license, development and commercialization agreement with Elanco Animal Health, a division of Eli Lilly and Company.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 11.67 (-0.33), JNJ: 119.18 (+0.27), HRTX: 19.76 (-0.10), GILD: 81.70 (unch), LJPC: 26.00 (-0.27), PETX: 9.13 (+0.01)
First Week of February 2017 Options Trading For Aratana Therapeutics
StockOptionsChannel.com - Tue Jun 28, 9:33AM CDT
Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration...
PETX: 9.13 (+0.01)
Aratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic
PR Newswire - Thu Jun 02, 8:23AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company received a technical section complete letter for chemistry, manufacturing and controls (CMC) for NOCITA® (bupivacaine liposome injectable suspension) from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). Nocita is being investigated as a therapeutic option to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and works as a long-acting local anesthetic designed to provide up to 72 hours of post-operative pain control.
PETX: 9.13 (+0.01)
Aratana Therapeutics to Participate at Two Upcoming Investor Conferences
PR Newswire - Mon May 23, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
PETX: 9.13 (+0.01)
Aratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution)
PR Newswire - Tue May 17, 4:46PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017.
PETX: 9.13 (+0.01)
Aratana reports 1Q loss
Automated Insights - Thu May 05, 5:38PM CDT
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $18.1 million in its first quarter.
PETX: 9.13 (+0.01)
Aratana Therapeutics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Aratana Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Mon May 02, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
PETX: 9.13 (+0.01)
Aratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health
PR Newswire - Mon Apr 25, 3:10PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals will host a conference call today, Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) that was announced this afternoon.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Aratana, Elanco Announce Global Strategic Collaboration
PR Newswire - Mon Apr 25, 3:05PM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.
PETX: 9.13 (+0.01), LLY: 80.87 (+0.99)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 9.05 (+0.06), EBIO: 3.57 (+0.07), PTCT: 10.40 (-0.04), PETX: 9.13 (+0.01), ARRY: 3.59 (-0.05)
Aratana Therapeutics to Report First Quarter 2016 Financial Results
PR Newswire - Thu Apr 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
PETX: 9.13 (+0.01)
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:45AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise over 8% on the day.
CCXI: 5.16 (+0.02), PETX: 9.13 (+0.01)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 4.69 (+0.16), PETX: 9.13 (+0.01)
(0)
(0)Scroll down for more posts ▼